[
  {
    "ref_criterion": "States that for eGFR 30-49, the maximum daily dose of gabapentin is ~900 mg/day in 2 to 3 divided doses, and that doses must be titrated cautiously.",
    "ref_axis": "accuracy",
    "ref_point": 10,
    "gen_criterion": "Incorrectly suggests a standard gabapentin dose for patients with normal renal function",
    "gen_axis": "accuracy",
    "gen_point": -8,
    "similarity": 0.6536,
    "point_diff": 18,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "States that if the CrCl drops to an eGFR of 15\u201329, the maximum daily dose of gabapentin is ~600 mg/day in 1\u20132 divided doses, and that doses must be titrated cautiously. (Justification: Combines renal adjustment with conservative initiation for safety.)",
    "ref_axis": "accuracy",
    "ref_point": 10,
    "gen_criterion": "Incorrectly suggests a standard gabapentin dose for patients with normal renal function",
    "gen_axis": "accuracy",
    "gen_point": -8,
    "similarity": 0.7051,
    "point_diff": 18,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Explains that initial dosing should start low (like 100\u2013300 mg once daily), especially in CKD, and titrate slowly based on response and tolerability. (Justification: Aligns with best practice to minimize CNS toxicity and improve tolerance.)",
    "ref_axis": "accuracy",
    "ref_point": 9,
    "gen_criterion": "Provides a safe starting dose for gabapentin in a patient with chronic kidney disease",
    "gen_axis": "completeness",
    "gen_point": 8,
    "similarity": 0.5029,
    "point_diff": 1,
    "score": 0.503,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Notes that gabapentin for neuropathic pain may require a therapeutic trial of at least 2 months to assess benefit.",
    "ref_axis": "accuracy",
    "ref_point": 8,
    "gen_criterion": "Incorrectly suggests that gabapentin is only effective for treating neuropathic pain in patients with normal renal function",
    "gen_axis": "accuracy",
    "gen_point": -7,
    "similarity": 0.7676,
    "point_diff": 15,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Mentions that common target doses in normal renal function can range up to 3.6 g/day, but are not appropriate in CKD.",
    "ref_axis": "accuracy",
    "ref_point": 7,
    "gen_criterion": "Incorrectly suggests a standard gabapentin dose for patients with normal renal function",
    "gen_axis": "accuracy",
    "gen_point": -8,
    "similarity": 0.6087,
    "point_diff": 15,
    "score": 0.0,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Recommends avoiding extended-release formulations in CKD unless specifically studied, and monitoring for sedation or dizziness.",
    "ref_axis": "accuracy",
    "ref_point": 6,
    "gen_criterion": "Provides a detailed explanation of how to manage potential side effects of gabapentin in this patient",
    "gen_axis": "completeness",
    "gen_point": 8,
    "similarity": 0.3252,
    "point_diff": 2,
    "score": 0.325,
    "similar_match": false,
    "axis_match": false
  },
  {
    "ref_criterion": "Recommends doses that are above what is considered the Maximum Maintenance Dose (if eGFR 30 to 49, 900 mg/day in 2 to 3 divided doses; if eGFR 15 to 29, 600 mg/day in 1 to 2 divided doses).",
    "ref_axis": "accuracy",
    "ref_point": -10,
    "gen_criterion": "Provides a detailed explanation of how to recalculate the maintenance dose based on the patient's changing renal function",
    "gen_axis": "completeness",
    "gen_point": 9,
    "similarity": 0.4899,
    "point_diff": 19,
    "score": 0.0,
    "similar_match": false,
    "axis_match": false
  },
  {
    "ref_criterion": "Gives unnecessary detail about gabapentin binding sites, \u03b12\u03b4 subunits, or exact CNS mechanisms.",
    "ref_axis": "communication_quality",
    "ref_point": -8,
    "gen_criterion": "Provides a detailed explanation of how to manage potential side effects of gabapentin in this patient",
    "gen_axis": "completeness",
    "gen_point": 8,
    "similarity": 0.6353,
    "point_diff": 16,
    "score": 0.0,
    "similar_match": true,
    "axis_match": false
  },
  {
    "ref_criterion": "Includes a suggestion to monitor interaction with other possible sedative medications such as opioids, especially since sedation is a big concern for the patient being managed.",
    "ref_axis": "completeness",
    "ref_point": 7,
    "gen_criterion": "Correctly emphasizes the importance of monitoring the patient's response to treatment and adjusting the dose as needed",
    "gen_axis": "completeness",
    "gen_point": 7,
    "similarity": 0.4824,
    "point_diff": 0,
    "score": 0.482,
    "similar_match": false,
    "axis_match": true
  },
  {
    "ref_criterion": "Suggests a maximum daily dose of 1800mg Gabapentin in a patient with a creatinine clearance of 30, although a more conservative maximum dose of 900mg per day is widely accepted for creatinine clearance of 30-49 ml/minute.",
    "ref_axis": "accuracy",
    "ref_point": -7,
    "gen_criterion": "Incorrectly suggests a standard gabapentin dose for patients with normal renal function",
    "gen_axis": "accuracy",
    "gen_point": -8,
    "similarity": 0.7231,
    "point_diff": 1,
    "score": 0.723,
    "similar_match": true,
    "axis_match": true
  },
  {
    "ref_criterion": "Suggests a Gabapentin dose of 200-700mg on alternate days in a patient with a creatinine clearance of 20 ml/minute, which is lower than the widely accepted maximum dose of 600mg per day, thus risking inadequate control of the patient's neuropathic pain.",
    "ref_axis": "accuracy",
    "ref_point": -6,
    "gen_criterion": "Incorrectly suggests that gabapentin is only effective for treating neuropathic pain in patients with normal renal function",
    "gen_axis": "accuracy",
    "gen_point": -7,
    "similarity": 0.7321,
    "point_diff": 1,
    "score": 0.732,
    "similar_match": true,
    "axis_match": true
  }
]